当前位置: 首页 > 期刊 > 《昆明医学院学报》 > 20186
编号:13570897
高度近视及其并发症治疗的研究进展(3)
http://www.100md.com 2018年12月1日 《昆明医科大学报》 20186
     [12] Wu T-T, Kung Y-H.OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZ ATION.Retina, 2017,37(11): 2056–2061.

    [13] Traversi, Nuti C, Marigliani E,et al. Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization. Graefe"s Archive for Clinical and Experimental Ophthalmology, 2015,253(4).

    [14] Sakamoto T,Ishibashi T.Visualizing vitreous vitrectomy by triamcinolon.Graefes Arch Clin Exp Ophthalmol, 2009, 247: 1153- 1163.

    [15] Ji X, Wang J, Zhang J, et al. The effect of posterior scleral reinforcement for high myopia macular splitting. J. Int. Med. Res,2011,39(2).

    [16] Wei Y, Kang X.Surgical treatment progress of myopic strabismus fixus by Yokoyama's surgery .Zhonghua Yan Ke Za Zhi ,2014,50(7).

    [17] 亢曉丽, 韦严, 赵堪兴,等.改良的Yokoyama术治疗高度近视眼限制性内下斜视. 中华眼科杂志, 2011,11: 972-977.

    [18]Merino PS, Vera RE, Mari?as LG, et al.Botulinum toxin for treatment of restrictive strabismus. Optom ,2017, 10(3)., http://www.100md.com(种泽龙 李丽华)
上一页1 2 3